Spectra Biomedical Inc. deal

Spectra (Menlo Park, Calif.) entered into a three-year agreement with Glaxo Holdings p.l.c. to develop migraine therapeutics by identifying the genetic bases of common migraine.

Glaxo will provide annual research payments to support the development of Spectra's database of migraine sufferers and their families, and the collection of DNA samples from selected families. Based on the database information, Spectra will conduct analysis aimed at correlating specific DNA sequences with the disease. Glaxo will then identify, select and analyze specific genes for further study. ...